Urolithin A: The Muscle Molecule With a Longevity Marketing Problem

Pomegranate, Gut Bacteria, and a 45% Lifespan Extension in Worms

Here's how a billion-dollar supplement story begins: in 2016, a team from the Swiss Federal Institute of Technology published a study in Nature Medicine showing that a molecule called urolithin A extended lifespan in C. elegans — a tiny roundworm beloved by aging researchers — by 45.4%. The same compound improved exercise capacity in aged mice and appeared to rejuvenate mitochondrial function at a fundamental level.¹

The molecule wasn't synthesized in a lab. It was made by gut bacteria. When you eat pomegranates, walnuts, or certain berries, your intestinal microbiome converts compounds called ellagitannins into ellagic acid, then into urolithin A. It's a natural metabolite — your body has been making it (or trying to) for as long as humans have eaten fruit.

But there's a catch. Only about 40% of the population has the right gut bacteria to efficiently produce urolithin A from food.² The rest of us — the majority — produce little to none, regardless of how many pomegranates we consume. This biological bottleneck is what turned a fascinating piece of metabolic science into a supplement opportunity worth hundreds of millions of dollars.

The Swiss company Amazentis SA (now marketing as Timeline) developed a synthetic version called Mitopure®, filed for and received FDA GRAS status in 2018, and began selling it at $95–125 per month.³ Their pitch: skip the gut bacteria lottery and take the molecule directly. The clinical trials followed. And unlike most supplements in this space, there actually are clinical trials — randomized, double-blind, placebo-controlled studies published in top-tier journals.

I want to be clear about that upfront, because it matters. In a supplement landscape where most products coast on preclinical data and marketing, urolithin A has real human evidence. The question is whether that evidence supports what the marketing claims — and where the honest gaps remain.

Mitophagy: Your Cells' Quality Control System

To understand why urolithin A generated so much excitement, you need to understand mitophagy — one of the most elegant maintenance systems in cell biology.

Mitochondria are the organelles that produce energy inside your cells. They're essential, but they accumulate damage over time. Damaged mitochondria don't just become less efficient — they generate excess reactive oxygen species (free radicals) and trigger inflammatory signaling cascades that accelerate aging at the cellular level.⁴

Mitophagy is the process by which cells identify and selectively destroy these damaged mitochondria, clearing space for new, functional ones to be generated. Think of it as quality control: the cell tags defective mitochondria for removal via the PINK1/Parkin signaling pathway, wraps them in an autophagosome, and digests them in a lysosome. The raw materials get recycled. Fresh mitochondria take their place.

As we age, mitophagy slows down. Damaged mitochondria accumulate. Energy production drops. Inflammation increases. This mitochondrial decline is increasingly recognized as a hallmark of aging — not just a consequence but a potential driver of age-related disease.⁵

Urolithin A appears to activate this PINK1/Parkin mitophagy pathway. In preclinical models, the effect was dramatic: improved mitochondrial membrane potential, increased oxygen consumption, enhanced cellular energy output. In the C. elegans model, it literally made the worms live longer.¹

The preclinical story was strong enough to justify human trials. And the human trials, to their credit, were well-designed. Let's look at what they actually found.

Three RCTs, Real Results, and the Fine Print You Won't See in the Ads

There are three pivotal randomized controlled trials on urolithin A in humans. All three were funded by Amazentis SA — the company that manufactures and sells the product. I'll note this upfront because it matters for interpretation, even though the studies themselves were well-conducted.

Let me be precise about what this means. A 12% improvement in leg muscle strength is real and measurable. It's comparable to what you'd expect from a modest resistance training program in sedentary adults. The 6-minute walk test improvement of 33 meters exceeds the commonly accepted threshold for clinical significance in older populations. These are not trivial findings.

But the primary endpoint — peak power output — failed. The study found benefits on secondary endpoints while missing its main target. This is a pattern that should make any careful reader pause. Secondary endpoints that succeed when the primary fails are hypothesis-generating, not confirmatory.

So what's the honest summary? Urolithin A at 500–1,000 mg/day appears to modestly improve muscle endurance and strength in untrained middle-aged and older adults over four months. It reduces several inflammatory biomarkers. It's safe and well-tolerated. These are genuine, if modest, findings published in legitimate peer-reviewed journals.

But here's what the trials have not demonstrated: changes in muscle mass, improvements in cardiovascular outcomes, cognitive benefits, or any measure of actual longevity. Every trial was short (four months maximum), small (n=36 to n=88), and funded entirely by the manufacturer.

Nature Aging Published It. The Internet Lost Its Mind.

In early 2025, the MitoImmune study landed in Nature Aging and generated a wave of headlines suggesting urolithin A could "rejuvenate" the aging immune system.⁹ Social media ran with it. Influencers declared it the next breakthrough in longevity medicine. Timeline's marketing team had a very good week.

The actual study enrolled 50 healthy adults aged 45–70 in a double-blind, placebo-controlled design. Participants took 1,000 mg/day for just four weeks. The results showed expanded naive-like CD8+ T cells (a type of immune cell that declines with age), increased fatty acid oxidation in those cells, elevated natural killer cell counts, and improved microbial clearance capacity.

I want to be fair: these immune biomarker shifts are scientifically interesting. The expansion of naive CD8+ T cells in a four-week window is noteworthy because this cell population is a well-established marker of immunosenescence — the age-related decline in immune function. If these effects are durable and translate to clinical outcomes, they would be significant.

But they're biomarkers. No one in this study was shown to have a stronger immune response to an actual pathogen. No one avoided an infection. No one recovered faster from illness. The leap from "more naive T cells in a blood draw" to "rejuvenated immune system" requires data that doesn't exist yet. The study's borderline p-value (0.04) on 50 participants also warrants caution — in a slightly larger or different sample, this finding might not replicate.

Urolithin A by the Numbers

What the Product Page Says vs. What the Evidence Shows

Here's where I have a problem. The clinical evidence for urolithin A is specific and limited: modest improvements in muscle strength and endurance, reductions in inflammatory biomarkers, and early signals of immune cell activation. All in short-term studies. All funded by the manufacturer.

The marketing is something else entirely. Timeline positions Mitopure® as a comprehensive "cellular health" and "longevity" supplement. The language on their website and in advertising implies broad anti-aging benefits — cellular rejuvenation, mitochondrial renewal, immune system restoration. The visual branding evokes clinical sophistication. The price tag ($95–125/month) positions it as a premium health investment.¹⁰

But there is no human evidence that urolithin A extends lifespan, prevents age-related disease, reduces cardiovascular risk, improves cognitive function, or slows biological aging by any validated measure. The lifespan extension data comes from worms. The cardiovascular data is preclinical.¹¹ The Alzheimer's data is from mouse models.¹² These are different categories of evidence than what's being implied to consumers.

A 2024 systematic review of all human trials concluded that urolithin A showed dose-dependent anti-inflammatory effects but "no meaningful effect on cardiovascular outcomes, anthropometrics, or physical function" broadly defined — and stated that evidence was "insufficient for broad geroprotective claims."¹³

A 2025 systematic review specifically focused on muscle outcomes was even more direct: "insufficient evidence exists to support the use of urolithin A to improve muscle function in any population at present."¹⁴

There's also the conflict-of-interest issue I keep returning to because it's important. Every major human trial was funded by the company selling the product. Multiple researchers across these studies had financial relationships with Amazentis — as employees, board members, consultants, or scientific advisors. The funder participated in study design, data analysis, and publication decisions.^6,7,8,9

This doesn't mean the data is fabricated. These are published in high-quality journals with peer review. But it does mean we should apply a higher evidence bar before accepting the conclusions at face value. In pharmacology, we require independent replication before approving drugs. No independent academic group has yet conducted a large-scale confirmatory trial of urolithin A. Until that happens, the evidence remains promising but incomplete.

One aspect of the urolithin A story that is genuinely useful: the bioavailability data. A 2021 study in the European Journal of Clinical Nutrition showed that 500 mg of supplemental urolithin A produces plasma levels approximately six times higher than drinking 240 mL of pomegranate juice.¹⁵ For the estimated 60% of the population that cannot efficiently convert dietary ellagitannins to urolithin A through their gut microbiome, direct supplementation is the only reliable way to achieve meaningful blood levels.

This is arguably the strongest practical argument for the product — not as a longevity miracle, but as a bioavailable form of a potentially beneficial metabolite that most people cannot produce on their own. Whether that metabolite is worth $1,500 per year is a different question, and one that depends on how much weight you give to four-month trials funded by the manufacturer.

There's also a quality-control issue. In 2023, Timeline tested two competing urolithin A products purchased from Amazon and reportedly found zero detectable urolithin A in either, despite label claims.¹⁰ If you do decide to try urolithin A, the branded Mitopure® product is currently the only version with clinical data behind it — and the only one that's been independently verified to contain what it claims.

What Should Give You Pause

Where the Evidence Actually Stands